8-K: BioCryst Exceeds 2025 ORLADEYO Revenue, Boosts 2026 Outlook

BioCryst Pharmaceuticals announced preliminary 2025 ORLADEYO net revenue surpassed guidance and provided strong 2026 financial projections, including the impact of the Astria Therapeutics acquisition.

Summary

• Preliminary, unaudited ORLADEYO net revenue for the fourth quarter of 2025 was $151 million, representing a 22% year-over-year increase, or 36% on a comparable basis excluding European revenue.
• Preliminary, unaudited ORLADEYO net revenue for the full year 2025 reached $601 million, a 37% year-over-year increase, exceeding the company's prior guidance range of $590 million to $600 million.
• Excluding European ORLADEYO revenue, full year 2025 net revenue was $563 million, a 43% year-over-year increase on a comparable basis.
• Preliminary, unaudited cash, cash equivalents, restricted cash & investments as of December 31, 2025, stood at $338 million.
• The company expects full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million.
• Total revenue for full year 2026, including RAPIVAB, is projected to be between $635 million and $660 million.
• Non-GAAP operating expenses for full year 2026 (excluding stock-based compensation, restructuring, and transaction-related costs) are expected to be between $380 million and $390 million.
• Upon the expected close of the Astria Therapeutics acquisition in Q1 2026, an additional $70 million to $80 million in non-GAAP operating expenses are anticipated for 2026 to support Phase 3 enrollment of navenibart and commercial readiness.
• Total non-GAAP operating expenses for full year 2026, including the Astria acquisition, are projected to be between $450 million and $470 million.
• The company expects continued non-GAAP profitability in 2026, even after the Astria acquisition.

Sentiment

Score: 8

Explanation: The sentiment is positive due to strong ORLADEYO revenue exceeding guidance, robust year-over-year growth, and optimistic 2026 financial guidance. The strategic acquisition of Astria Therapeutics is a significant growth driver, although it introduces increased operating expenses and integration risks.

Positives

• Full year 2025 ORLADEYO net revenue of $601 million exceeded the prior guidance range of $590 million to $600 million.
• Strong year-over-year growth in ORLADEYO net revenue: +37% for full year 2025 and +22% for Q4 2025 (+36% comparable).
• Projected continued non-GAAP profitability in 2026, even with the expected acquisition of Astria Therapeutics.
• Solid cash position with $338 million in cash, cash equivalents, restricted cash & investments as of December 31, 2025.
• Strategic proposed acquisition of Astria Therapeutics is expected to expand impact for HAE patients and advance the pipeline.
• Positive outlook for 2026 with global net ORLADEYO revenue guidance of $625 million to $645 million and total revenue guidance of $635 million to $660 million.

Negatives

• Increased non-GAAP operating expenses projected for 2026, rising to $450 million to $470 million with the Astria acquisition, primarily for Phase 3 enrollment and commercial readiness.
• Reliance on non-GAAP financial measures, which exclude certain items like stock-based compensation and transaction-related costs, potentially obscuring GAAP profitability.

Risks

• Actual results may differ materially from preliminary, unaudited results and forward-looking statements due to known and unknown risks and uncertainties.
• Ability to successfully implement or maintain commercialization plans for ORLADEYO.
• Ability to successfully progress pipeline development plans, including meeting expected timelines.
• Results of partnerships with third parties may not meet current expectations.
• Risks related to government actions, including pricing decisions, which may not be taken as expected or at all.
• Commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand.
• Ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not yield positive results.
• Outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials; interim results do not necessarily predict final results.
• Inability to enroll the required number of subjects in planned clinical trials of product candidates.
• FDA or other applicable regulatory agencies may require additional studies, delay regulatory clearances, impose restrictions, or withhold, delay, or withdraw market approval.
• Product candidates, if approved, may not achieve market acceptance.
• Ability to successfully manage growth and compete effectively.
• Timing for achieving or sustainability of profitability and positive cash flow may not meet management's expectations.
• Statements and projections regarding financial guidance and goals may differ from actual results or may not be achieved on expected timelines.
• Actual financial results may not be consistent with expectations, including revenue, operating expenses, and cash usage.
• Risks related to the Astria Therapeutics acquisition, including the possibility of termination, failure to obtain stockholder approval, failure to satisfy other conditions, or anticipated benefits not being realized.
• Potential for significant indebtedness to be incurred in connection with the Astria acquisition and the need to generate sufficient cash flows to service and repay such debt.
• The acquisition may be more expensive to complete than anticipated, or divert management's attention from ongoing business operations.
• Potential adverse reactions or changes to business or employee relationships resulting from the completion of the acquisition.
• Risks relating to the potential dilutive effect of shares of BioCryst common stock to be issued in the acquisition.

Future Outlook

The company anticipates continued strong demand for ORLADEYO, solidifying its position as a leading HAE treatment. The proposed acquisition of Astria Therapeutics is expected to expand the company's impact for HAE patients and advance its pipeline. Management is confident in delivering innovative treatments for rare disease patients and driving sustainable growth well into the future, projecting continued non-GAAP profitability in 2026 even after the Astria acquisition.

Management Comments

• "2025 was a transformative year for BioCryst. Continued strong demand for ORLADEYO and outstanding patient outcomes have solidified its position as the leading oral, once-daily prophylaxis treatment for HAE."
• "The successful sale of our European ORLADEYO business further strengthened our financial position, and the proposed acquisition of Astria marks an exciting step toward expanding our impact for HAE patients."
• "With our advancing pipeline, flexibility to continue pursuing value-creating business development opportunities, and dedication of our exceptional team, we are confident in our ability to deliver innovative treatments for rare disease patients and drive sustainable growth well into the future."

Industry Context

This announcement highlights BioCryst's continued leadership in the hereditary angioedema (HAE) market with ORLADEYO, an oral, once-daily prophylaxis treatment. The strategic acquisition of Astria Therapeutics signals a move to expand its rare disease portfolio and pipeline, aligning with broader industry trends of consolidation and focus on high-growth specialty markets. The presentation at the J.P. Morgan Healthcare Conference underscores the company's engagement with the investment community and its position within the biotechnology sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. The focus is on internal performance metrics and future guidance.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue performance and exceeding guidance, increased future revenue guidance, and strategic growth through acquisition. However, potential dilution from shares issued for the Astria acquisition and increased indebtedness are noted risks.
• Patients (HAE): Continued strong availability and demand for ORLADEYO, with the potential for new treatment options (navenibart) from the Astria acquisition.
• Employees: Integration of Astria Therapeutics employees and potential for operational synergies, which could lead to organizational changes.
• Creditors: Potential for increased indebtedness due to the Astria acquisition, requiring sufficient cash flow generation for servicing and repayment.

Next Steps

• Present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2026, at 1:30 p.m. ET.
• Expected close of the proposed acquisition of Astria Therapeutics in Q1 2026.
• Support ongoing Phase 3 enrollment of navenibart (from Astria acquisition).
• Conduct commercial readiness manufacturing activities for navenibart.
• Complete the navenibart trial and realize the full impact of operational synergies over the next two years.

Key Dates

Recommendation

While BioCryst demonstrated strong performance with ORLADEYO exceeding guidance and provided optimistic 2026 projections, the proposed acquisition of Astria Therapeutics introduces significant integration risks, increased operating expenses, and potential indebtedness. The long-term success hinges on the effective integration of Astria and successful progression of its pipeline, warranting a cautious 'hold' stance until more clarity emerges on these fronts.

Keywords

BioCryst, ORLADEYO, berotralstat, HAE, hereditary angioedema, biotechnology, rare disease, financial results, revenue guidance, Astria Therapeutics, acquisition, operating expenses, cash position, pharmaceuticals